Definiens, the pioneer in Tissue Phenomics® solutions for diagnostics development and commercialization, is expanding its presence in the U.S. to meet growing customer needs. The company opened its Boston office last year, and since then has experienced significant growth in providing tissue-based services to pharmaceutical companies, academic medical centers, comprehensive cancer centers and biotech companies in North America, prompting further expansion in the market.
The office, based just outside Boston in Cambridge, MA, will become the company’s new U.S. headquarters.
“Our Boston office is located in a life sciences hot spot. As we continue to grow and service more customers, Boston is a natural choice to become our new U.S. headquarters,” said Michael Rasche, Senior Vice President and Head of Global Sales and Business Development at Definiens. “With close proximity to a large number of pharmaceutical and biopharma companies, Boston will be the primary location for our commercial teams and our project managers to execute biomarker and companion diagnostic development projects in North America.”
Over the last year Definiens has expanded its Tissue Phenomics offerings, which enable scientists to better identify biomarkers, develop diagnostic tests and advance precision medicine in oncology. It also recently launched an Immunoprofiling service to enable immuno-oncology researchers to quickly screen target biomarkers and measure immune response, as well as the company’s first Clinical Development Offering, making it a comprehensive provider of tissue-based services from discovery to commercialization. The company will continue to focus on enhancing its offerings for customers, and as part of that will be recruiting additional technical engineering employees as well as commercial leaders for the Boston office.
“We have brought on a number of talented new team members over the last few months to meet growing customer demand in North America, and look forward to further expanding the team in Boston to better serve our client base in this market,” said Rasche.
As part of the U.S. expansion, the company will concentrate its office activities in the new Boston HQ offices and as a consequence will be closing its office in Carlsbad, California.
To learn more about Definiens, visit www.definiens.com.
Definiens is the pioneering provider of Tissue Phenomics® solutions for biomarker and companion diagnostics development and commercialization. Definiens’ technology empowers smarter tissue-based diagnostics by leveraging quantitative tissue readouts and other big data sources. By enabling the development of powerful and precise assays for patient stratification and clinical trial enrollment, Definiens aims to dramatically improve patient outcomes. Definiens' Tissue Phenomics approach was awarded the 2013 Frost and Sullivan Company of the Year Award for Global Tissue Diagnostics and Pathology Imaging. For more information, please visit: www.definiens.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160830005041/en/Business Wire
Last updated on: 30/08/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.